Significant reduction seen in mortality, specifically among patients transfused with plasma within 72 hours
FRIDAY, Aug. 14, 2020 (HealthDay News) — Transfusion of convalescent plasma is efficacious in patients with severe COVID-19, according to a study published online Aug. 11 in The American Journal of Pathology.
Eric Salazar, M.D., Ph.D., from Houston Methodist Hospital, and colleagues conducted a prospective, propensity score-matched study to examine the efficacy of COVID-19 convalescent plasma transfusion versus standard of care for severe and/or critical COVID-19. An interim analysis of 316 patients enrolled from March 28 to July 6, 2020, was performed.
Of the patients, 136 met a 28-day outcome and were matched to 251 nontransfused control patients with COVID-19. The researchers found that within 28 days, there was a significant reduction in mortality, specifically among patients transfused with plasma within 72 hours of admission, with an antispike protein receptor binding domain titer of ≥1:1,350.
“Our studies to date show the treatment is safe and, in a promising number of patients, effective,” a coauthor said in a statement. “While convalescent plasma therapy remains experimental and we have more research to do and data to collect, we now have more evidence than ever that this century-old plasma therapy has merit, is safe, and can help reduce the death rate from this virus.”
One author disclosed financial ties to Regeneron.
.jpg)
Mortality Lowest at Hemoglobin Concentrations Above WHO Thresholds 
Oral Vitamin C Active in Clonal Cytopenia of Undetermined Significance 
~16 Percent of COVID Cases Develop Postacute Sequelae of SARS-CoV-2 
Ultra-Endurance Running Accelerates Red Blood Cell Aging 
Functional Decline Precedes Cardiovascular Disease Events by Many Years 
Midlife Employment Instability Linked to Later Cognitive Deficits 
Better Cardiovascular Health Inversely Linked to Overactive Bladder 
Estimated Glucose Disposal Rate Inversely Linked to Benign Prostatic Hyperplasia 
